Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

Phase 2

Completed

• Conditions: Prostate Cancer
• Interventions: Drug: radium-223 dichloride

• Registration Number: NCT03062254
• Lead Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

Brief Summary

Broadly, the objective of this study is to evaluate the fractional decline of intensity of tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT in bone metastases from prostate cancer following treatment with radium-223 as a surrogate marker for tumor cell killing.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-02-20
• Study First Submitted QC: 2017-02-22
• Study First Posted: 2017-02-23
• Study Start: 2018-03-22
• Primary Completion: 2020-07-15
• Study Completion: 2021-07-15
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-20
• Last Update Posted: 2021-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 14

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Radium-223	radium-223 dichloride	-

Primary Outcome Measures

Name	Time	Method
SUV-max	6 months	fractional decline of intensity of tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT

Trial Locations

Locations (1)

Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada